Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04313881
Title Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)
Acronym ENHANCE
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gilead Sciences
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS


No variant requirements are available.